Panelist: Jawad Hasan
Dr. Jawad M. Hasan has spent his career at the intersection of medicine, innovation, and patient safety. For more than 17 years, he has guided groundbreaking therapies from early clinical trials through global regulatory approvals, ensuring the highest standards of safety assessment and evaluation. As Global Safety Head at AstraZeneca, Alexion Rare Disease Unit, Dr. Hasan leads diverse teams of physicians and scientists, shaping strategy for the development of products in multiple rare disease indications. Known for building high-performing safety organizations and fostering a culture of collaboration and scientific rigor, he has steered companies through critical FDA and EMA interactions, major product launches, and complex benefit–risk evaluations. Driven by a deep commitment to patients, Dr. Hasan blends clinical insight with strategic leadership to bring innovative medicines to those who need them most.